| In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435 O Lenz, T Verbinnen, TI Lin, L Vijgen, MD Cummings, J Lindberg, ... Antimicrobial agents and chemotherapy 54 (5), 1878-1887, 2010 | 258 | 2010 |
| In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor TI Lin, O Lenz, G Fanning, T Verbinnen, F Delouvroy, A Scholliers, ... Antimicrobial agents and chemotherapy 53 (4), 1377-1385, 2009 | 231 | 2009 |
| Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies O Lenz, T Verbinnen, B Fevery, L Tambuyzer, L Vijgen, M Peeters, ... Journal of hepatology 62 (5), 1008-1014, 2015 | 165 | 2015 |
| Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region C Sarrazin, E Lathouwers, M Peeters, B Daems, A Buelens, J Witek, ... Antiviral research 116, 10-16, 2015 | 138 | 2015 |
| Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised … KR Reddy, S Zeuzem, F Zoulim, O Weiland, A Horban, C Stanciu, ... The Lancet infectious diseases 15 (1), 27-35, 2015 | 113 | 2015 |
| JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection F Zoulim, O Lenz, JJ Vandenbossche, W Talloen, T Verbinnen, I Moscalu, ... Gastroenterology 159 (2), 521-533. e9, 2020 | 99 | 2020 |
| Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing T Verbinnen, H Van Marck, I Vandenbroucke, L Vijgen, M Claes, TI Lin, ... Journal of virology 84 (21), 11124-11133, 2010 | 93 | 2010 |
| Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus–infected patients following TMC435 monotherapy O Lenz, J de Bruijne, L Vijgen, T Verbinnen, C Weegink, H Van Marck, ... Gastroenterology 143 (5), 1176-1178. e6, 2012 | 49 | 2012 |
| Chronic fatigue syndrome: A biological approach P Englebienne, K De Meirleir CRC Press, 2002 | 41 | 2002 |
| Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures JM Pawlotsky Seminars in Liver Disease 39 (03), 354-368, 2019 | 40 | 2019 |
| Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data H Janssen, J Hou, T Asselah, H Chan, F Zoulim, Y Tanaka, E Janczewska, ... Journal of Hepatology 73, S129-S130, 2020 | 33 | 2020 |
| Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos (t) ide analogue in patients with chronic hepatitis B infection HLA Janssen, J Hou, T Asselah, HLY Chan, F Zoulim, Y Tanaka, ... Gut 72 (7), 1385-1398, 2023 | 32 | 2023 |
| Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype AH clinical isolates and core site-directed mutants in vitro JM Berke, Y Tan, T Verbinnen, P Dehertogh, K Vergauwen, A Vos, O Lenz, ... Antiviral research 144, 205-215, 2017 | 31 | 2017 |
| In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants T Verbinnen, B Fevery, L Vijgen, T Jacobs, S De Meyer, O Lenz Antimicrobial Agents and Chemotherapy 59 (12), 7548-7557, 2015 | 28 | 2015 |
| A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin … KR Reddy, S Zeuzem, F Zoulim, O Weiland, A Horban, C Stanciu, ... Hepatol Int 8, S397, 2014 | 28 | 2014 |
| Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors P Raboisson, O Lenz, TI Lin, D Surleraux, S Chakravarty, A Scholliers, ... Bioorganic & medicinal chemistry letters 17 (7), 1843-1849, 2007 | 22 | 2007 |
| Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro T Verbinnen, Y Tan, G Wang, P Dehertogh, K Vergauwen, JM Neefs, ... Journal of Antimicrobial Chemotherapy 75 (9), 2526-2534, 2020 | 21 | 2020 |
| Resistance analyses of HCV isolates from patients treated with simeprevir in phase 2b/3 studies: 1101 O Lenz, B Fevery, T Verbinnen, L Tambuyzer, L Vijgen, M Peeters, ... Hepatology 58, 743A-744A, 2013 | 21 | 2013 |
| Efficacy and safety of the siRNA JNJ-3989 and/OR the Capsid Assembly Modulator (CAM) JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB): results from the … MF Yuen, T Asselah, IM Jacobson, MR Brunetto, HL Janssen, T Takehara, ... Hepatology 74 (6), 1390A-1391A, 2021 | 20 | 2021 |
| O004: On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after … X Forns, M Berenguer, K Herzer, M Sterneck, MF Donato, P Andreone, ... Journal of Hepatology, S191-S192, 2015 | 20 | 2015 |
